Adagene Inc.

NASDAQ:ADAG

Biotechnology

Healthcare
$1.82 +3.68%

+$0.13 today

Market cap
$68.52M
Beta
0.59
P/E (TTM)
-7.9
EPS (TTM)
-$0.47
52W Low $1.30High $4.75

Volume 1.30M

Average 0.21M

ADAG Pre-Tax Margin

Income before tax as a percentage of revenue.

Adagene Inc.NASDAQ: ADAG

Pre-Tax Margin · Q4 FY2025 · quarter ended Dec 2025

Pre-tax margin widens to -57.8%

Pre-tax margin was -57.8% in Q4 FY2025, up 24104.6 pp from a year earlier. On a trailing-twelve-month basis it was -3980.4%, down 3829.4 pp year over year. Over 3 fiscal years it widened by 622.2 pp.

Context

  • Pre-tax margin widened in 2 of the last 3 fiscal years.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterDec 2025
-57.8%— QoQ
Last fiscal yearDec 2025
-233.4%+32170.0 pp YoY
LTMJun 2024
-3980.4%-3829.4 pp YoY
Pre-Tax Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+24104.6 pp——
1 year+32170.0 pp——
3 years+622.2 pp——
5 years——
10 years——

Pre-Tax Margin history

Percent of revenue · from the income statement

Latest · FY2025
-233.4%
Year-over-year change
+32170.0pp

Pre-Tax Margin vs competitors

How ADAG compares with its peers on the latest reported figures

  • ADAG's LTM Jun 2024 pre-tax margin of -3980.4% is the lowest of the 5 companies compared; the peer median is -759.3%.
  • Over three fiscal years its change of +622.2 pp compares with a peer median of -188.5 pp.
ADAG Competitors Peer median
Pre-Tax Margin for ADAG and competitors
Company Period LTM level YoY 3-year change
FBIOFortress Biotech, Inc.LTM Mar 2026201.4% +385.1 pp+228.8 pp
NTRBNutriband Inc.LTM Apr 2026-448.4% -32.6 pp-188.5 pp
NRXPNRx Pharmaceuticals, Inc.LTM Mar 2026-1070.3% ——
TCRXTScan Therapeutics, Inc.LTM Mar 2026-1360.6% +1613.5 pp-767.6 pp
ADAGAdagene Inc.LTM Jun 2024-3980.4% —+622.2 pp
XBITXBiotech Inc.FY2025— ——
GANXGain Therapeutics, Inc.FY2025— ——
OSTXOS Therapies IncorporatedFY2025— ——
ACETAdicet Bio, Inc.FY2025— ——
Peer median (excluding ADAG) -759.3%+385.1 pp-188.5 pp

Competitors are the stored peer set for ADAG. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue10.18M9.29M18.11M103.2K7.67M
Cost of Revenue00000
Gross Profit10.18M9.29M18.11M(823.04K)7.67M
Gross Margin100.0%100.0%100.0%-797.5%100.0%
Research & Development68.1M81.34M36.64M28.78M22.03M
Selling, General & Admin14.44M11.87M8.67M7.27M7.08M
Operating Expenses82.54M93.21M41.83M36.05M29.11M
Depreciation & Amortization1.13M1.43M1.21M926.25K589.79K
EBITDA(69.99M)(77.39M)(14.95M)(31.66M)(16.85M)
EBITDA Margin-687.8%-832.8%-82.5%-30680.5%-219.7%
Operating Income(72.36M)(83.92M)(23.72M)(35.95M)(21.44M)
Operating Margin-711.2%-903.1%-131.0%-34835.4%-279.5%
Interest Income76.17K377.5K4.28M3.8M2.3M
Interest Expense363.76K693.32K1.11M851.87K463.13K
Other Income / Expenses887.77K4.41M6.46M2.51M3.53M
Income Before Tax(71.48M)(79.51M)(17.25M)(33.44M)(17.91M)
Pre-Tax Margin-702.5%-855.6%-95.3%-32403.5%-233.4%
Income Tax Expense1.7M459.06K1.69M(17.55K)(297.86K)
Net Income(73.18M)(79.97M)(18.95M)(33.42M)(17.61M)
Net Margin-719.2%-860.6%-104.6%-32386.4%-229.6%
EPS (Basic)(2.29)(2.31)(0.55)(0.95)(0.46)
EPS (Diluted)(2.29)(2.31)(0.54)(0.95)(0.46)
Weighted Avg Shares32.02M34.65M34.64M36.02M37.76M
Weighted Avg Shares (Diluted)32.02M34.65M35.03M36.02M37.76M

Adagene Inc.

NASDAQ:ADAG

Intrinsic Alpha fair value

Locked

Current Price

$1.82

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.